250 related articles for article (PubMed ID: 24895338)
1. Impact of MLL5 expression on decitabine efficacy and DNA methylation in acute myeloid leukemia.
Yun H; Damm F; Yap D; Schwarzer A; Chaturvedi A; Jyotsana N; Lübbert M; Bullinger L; Döhner K; Geffers R; Aparicio S; Humphries RK; Ganser A; Heuser M
Haematologica; 2014 Sep; 99(9):1456-64. PubMed ID: 24895338
[TBL] [Abstract][Full Text] [Related]
2. DNMT3A mutations and response to the hypomethylating agent decitabine in acute myeloid leukemia.
Metzeler KH; Walker A; Geyer S; Garzon R; Klisovic RB; Bloomfield CD; Blum W; Marcucci G
Leukemia; 2012 May; 26(5):1106-7. PubMed ID: 22124213
[No Abstract] [Full Text] [Related]
3. MLL5 expression as a biomarker for DNA hypermethylation and sensitivity to epigenetic therapy.
Milne TA
Haematologica; 2014 Sep; 99(9):1405-7. PubMed ID: 25176980
[No Abstract] [Full Text] [Related]
4. Analysis of genome-wide methylation and gene expression induced by 5-aza-2'-deoxycytidine identifies BCL2L10 as a frequent methylation target in acute myeloid leukemia.
Fabiani E; Leone G; Giachelia M; D'alo' F; Greco M; Criscuolo M; Guidi F; Rutella S; Hohaus S; Voso MT
Leuk Lymphoma; 2010 Dec; 51(12):2275-84. PubMed ID: 21077739
[TBL] [Abstract][Full Text] [Related]
5. Targeting epigenetic pathways in acute myeloid leukemia and myelodysplastic syndrome: a systematic review of hypomethylating agents trials.
Yun S; Vincelette ND; Abraham I; Robertson KD; Fernandez-Zapico ME; Patnaik MM
Clin Epigenetics; 2016; 8():68. PubMed ID: 27307795
[TBL] [Abstract][Full Text] [Related]
6. A multicenter phase II trial of decitabine as first-line treatment for older patients with acute myeloid leukemia judged unfit for induction chemotherapy.
Lübbert M; Rüter BH; Claus R; Schmoor C; Schmid M; Germing U; Kuendgen A; Rethwisch V; Ganser A; Platzbecker U; Galm O; Brugger W; Heil G; Hackanson B; Deschler B; Döhner K; Hagemeijer A; Wijermans PW; Döhner H
Haematologica; 2012 Mar; 97(3):393-401. PubMed ID: 22058219
[TBL] [Abstract][Full Text] [Related]
7. The euphoria of hypomethylating agents in MDS and AML: is it justified?
Sekeres MA
Best Pract Res Clin Haematol; 2013 Sep; 26(3):275-8. PubMed ID: 24309530
[TBL] [Abstract][Full Text] [Related]
8. Decitabine induces very early in vivo DNA methylation changes in blasts from patients with acute myeloid leukemia.
Claus R; Pfeifer D; Almstedt M; Zucknick M; Hackanson B; Plass C; Lübbert M
Leuk Res; 2013 Feb; 37(2):190-6. PubMed ID: 23158571
[TBL] [Abstract][Full Text] [Related]
9. Predictive factors for response and survival in elderly acute myeloid leukemia patients treated with hypomethylating agents: a real-life experience.
Pepe S; Scalzulli E; Colafigli G; Di Prima A; Diverio D; Mancini M; Latagliata R; Martelli M; Foà R; Breccia M
Ann Hematol; 2020 Oct; 99(10):2405-2416. PubMed ID: 32813071
[TBL] [Abstract][Full Text] [Related]
10. Clinical update on hypomethylating agents.
Duchmann M; Itzykson R
Int J Hematol; 2019 Aug; 110(2):161-169. PubMed ID: 31020568
[TBL] [Abstract][Full Text] [Related]
11. The cancer‑testis antigen NXF2 is activated by the hypomethylating agent decitabine in acute leukemia cells in vitro and in vivo.
Zhou J; Li Y; Yao Y; Wang L; Gao L; Gao X; Luo X; Li J; Jiang M; Zhou M; Wang L; Yu L
Mol Med Rep; 2013 Nov; 8(5):1549-55. PubMed ID: 24002123
[TBL] [Abstract][Full Text] [Related]
12. Genome-wide methylation profiling in decitabine-treated patients with acute myeloid leukemia.
Yan P; Frankhouser D; Murphy M; Tam HH; Rodriguez B; Curfman J; Trimarchi M; Geyer S; Wu YZ; Whitman SP; Metzeler K; Walker A; Klisovic R; Jacob S; Grever MR; Byrd JC; Bloomfield CD; Garzon R; Blum W; Caligiuri MA; Bundschuh R; Marcucci G
Blood; 2012 Sep; 120(12):2466-74. PubMed ID: 22786882
[TBL] [Abstract][Full Text] [Related]
13. Lack of objective response of myelodysplastic syndromes and acute myeloid leukemia to decitabine after failure of azacitidine.
Duong VH; Bhatnagar B; Zandberg DP; Vannorsdall EJ; Tidwell ML; Chen Q; Baer MR
Leuk Lymphoma; 2015 Jun; 56(6):1718-22. PubMed ID: 25263320
[TBL] [Abstract][Full Text] [Related]
14. Decitabine has a biphasic effect on natural killer cell viability, phenotype, and function under proliferative conditions.
Kopp LM; Ray A; Denman CJ; Senyukov VS; Somanchi SS; Zhu S; Lee DA
Mol Immunol; 2013 Jul; 54(3-4):296-301. PubMed ID: 23328088
[TBL] [Abstract][Full Text] [Related]
15. Clinical development of demethylating agents in hematology.
Navada SC; Steinmann J; Lübbert M; Silverman LR
J Clin Invest; 2014 Jan; 124(1):40-6. PubMed ID: 24382388
[TBL] [Abstract][Full Text] [Related]
16. Digging deep into "dirty" drugs - modulation of the methylation machinery.
Pleyer L; Greil R
Drug Metab Rev; 2015 May; 47(2):252-79. PubMed ID: 25566693
[TBL] [Abstract][Full Text] [Related]
17. Decitabine effect on tumor global DNA methylation and other parameters in a phase I trial in refractory solid tumors and lymphomas.
Stewart DJ; Issa JP; Kurzrock R; Nunez MI; Jelinek J; Hong D; Oki Y; Guo Z; Gupta S; Wistuba II
Clin Cancer Res; 2009 Jun; 15(11):3881-8. PubMed ID: 19470736
[TBL] [Abstract][Full Text] [Related]
18. Characterization of in vitro and in vivo hypomethylating effects of decitabine in acute myeloid leukemia by a rapid, specific and sensitive LC-MS/MS method.
Liu Z; Liu S; Xie Z; Blum W; Perrotti D; Paschka P; Klisovic R; Byrd J; Chan KK; Marcucci G
Nucleic Acids Res; 2007; 35(5):e31. PubMed ID: 17264127
[TBL] [Abstract][Full Text] [Related]
19. Maintenance Therapy with Decitabine after Allogeneic Stem Cell Transplantation for Acute Myelogenous Leukemia and Myelodysplastic Syndrome.
Pusic I; Choi J; Fiala MA; Gao F; Holt M; Cashen AF; Vij R; Abboud CN; Stockerl-Goldstein KE; Jacoby MA; Uy GL; Westervelt P; DiPersio JF
Biol Blood Marrow Transplant; 2015 Oct; 21(10):1761-9. PubMed ID: 26055299
[TBL] [Abstract][Full Text] [Related]
20. Loss of MLL5 results in pleiotropic hematopoietic defects, reduced neutrophil immune function, and extreme sensitivity to DNA demethylation.
Heuser M; Yap DB; Leung M; de Algara TR; Tafech A; McKinney S; Dixon J; Thresher R; Colledge B; Carlton M; Humphries RK; Aparicio SA
Blood; 2009 Feb; 113(7):1432-43. PubMed ID: 18854576
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
